Trastuzumab emtansine (Kadcyla) in patients with HER2-positive inoperable or recurrent breast cancer in Japan

Trial Profile

Trastuzumab emtansine (Kadcyla) in patients with HER2-positive inoperable or recurrent breast cancer in Japan

Planning
Phase of Trial: Phase III

Latest Information Update: 02 Dec 2013

At a glance

  • Drugs Trastuzumab emtansine (Primary)
  • Indications Breast cancer
  • Focus Therapeutic Use
  • Sponsors Chugai Pharmaceutical
  • Most Recent Events

    • 02 Dec 2013 This trial is planned to continue until the price of Kadcyla is listed in Japan and the product is launched there, according to a Chugai Pharmaceutical media release.
    • 02 Dec 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top